Novartis' new Gilenya data fails to address NICE concerns as final decision looms
18 October 2011
Eleanor Malone
Please Login to read the full article.
18 October 2011
Eleanor Malone
eleanor.malone@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE work by Novartis pays off for Gilenya
- Novartis won't take 'hint' as German HTA says Gilenya offers little additional benefit
- Scots choose chewy Lipitor but refuse Zytiga, Sycrest and Gilenya
- NICE to review Fabre's Javlor again as comparison with unlicensed drugs deemed unfair
ANALYSIS
Other Informa Analysis
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
